Trastuzumab emtansine (NCT05673928)

Name: Trastuzumab emtansine trial for Metastatic Solid Tumor (NCT05673928)
Uploaded: 2026-10-31T21:51:21.971Z
Duration: 1 min 34 s
Description: Trastuzumab emtansine trial for Metastatic Solid Tumor (NCT05673928). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05673928.

A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB): a one-minute explainerNCT056739281 min

Trastuzumab emtansine trial for Metastatic Solid Tumor (NCT05673928). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with metastatic solid tumors meeting HER2 testing criteria and brain metastases not needing immediate treatment. Breast and gastric cancers require previous HER2-directed therapy. Extracranial disease must be measurable or evaluable.

The idea: tucatinib blocks HER2 growth signals; T-DM1 delivers a cell-division-blocking payload to HER2-bearing cells. Patients take tucatinib twice daily and receive T-DM1 infusions every three weeks. Researchers assess brain-tumor response and safety. Biopsies depend on safety and feasibility.

This phase 2 study plans 30 patients. Ecaterina Dumbrava leads at MD Anderson, Houston, the sole recruiting US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.